All Products

Semafull (Semaglutide)

RxNatco

Semafull is a semaglutide formulation manufactured by Natco Pharma Ltd., a prominent Indian pharmaceutical company known for producing high-quality specialty medications. Semaglutide belongs to the GLP-1 receptor agonist class and is used for type 2 diabetes management and weight reduction. Natco's Semafull offers a reliable and affordable semaglutide option, meeting the growing demand for GLP-1 therapies in India. Key Benefits: • GLP-1 receptor agonist with proven efficacy • Manufactured by Natco Pharma — a trusted specialty pharma name • Affordable pricing for wider patient access • Supports glycaemic control and weight management Indications: • Type 2 diabetes mellitus as an adjunct to diet and exercise • Chronic weight management in eligible patients Use as directed by your physician. Regular monitoring of blood glucose levels is recommended.

Sematrinity (Semaglutide)

RxSun Pharma

Sematrinity is a semaglutide formulation manufactured by Sun Pharmaceutical Industries Ltd. — India's largest pharmaceutical company. It contains semaglutide, a GLP-1 receptor agonist used for managing type 2 diabetes and supporting weight management. Sun Pharma's Sematrinity offers a cost-effective, high-quality semaglutide option for patients in India, manufactured to rigorous pharmaceutical standards. Key Benefits: • Effective GLP-1 receptor agonist therapy • Manufactured by Sun Pharma — India's #1 pharma company • Cost-effective semaglutide for broader patient access • Available in multiple dosage strengths Indications: • Type 2 diabetes mellitus (as adjunct to diet and exercise) • Weight management in eligible adults Always use under medical supervision with regular monitoring of blood glucose and weight.

Obeda (Semaglutide)

RxDr Reddy's

Obeda is an oral semaglutide formulation manufactured by Dr. Reddy's Laboratories — one of India's leading pharmaceutical companies. Semaglutide is a GLP-1 receptor agonist that helps manage type 2 diabetes and supports weight management. Obeda provides an accessible alternative to injectable semaglutide formulations, offering the benefits of GLP-1 receptor agonism in a convenient oral tablet form for eligible patients. Key Benefits: • GLP-1 receptor agonist for blood sugar control • Manufactured by Dr. Reddy's — trusted Indian pharma brand • Supports weight management in type 2 diabetes patients • Convenient dosing option Indications: • Adjunct to diet and exercise in adults with type 2 diabetes mellitus • Weight management in eligible patients Consult your prescribing physician regarding the appropriate dose and monitoring schedule.

Ozempic (Semaglutide) Pen

RxNovo Nordisk

Ozempic (semaglutide) is a once-weekly injectable prescription medicine by Novo Nordisk primarily approved for improving blood sugar control in adults with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular events (heart attack, stroke, or death) in adults with type 2 diabetes and known heart disease. Although Ozempic and Wegovy both contain semaglutide, Ozempic is specifically indicated for type 2 diabetes management at lower doses (up to 1mg), while Wegovy uses a higher 2.4mg dose approved for weight management. Key Benefits: • Lowers HbA1c (blood sugar) significantly • Reduces major cardiovascular events by 26% (SUSTAIN-6 trial) • Once-weekly injection — simple and convenient • Associated with meaningful weight reduction as a secondary effect Dosing: • Starting dose: 0.25mg/week for 4 weeks • Maintenance dose: 0.5mg–1mg/week Administration: Subcutaneous injection once weekly. Inject in abdomen, thigh, or upper arm.

Wegovy (Semaglutide) Pen

RxNovo Nordisk

Wegovy (semaglutide 2.4 mg) is a once-weekly injectable prescription medicine by Novo Nordisk for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related medical condition such as type 2 diabetes, high blood pressure, or high cholesterol. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1 (GLP-1), a gut hormone that regulates appetite and caloric intake. Wegovy is specifically approved for chronic weight management and is distinct from Ozempic (which targets diabetes). Key Benefits: • Up to 15–17% average body weight reduction in clinical trials • Once-weekly injection with step-up dosing protocol • Reduces appetite and caloric intake • FDA-approved for chronic weight management Dosing Schedule (step-up): 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg (maintenance dose, reached after 16 weeks) Administration: Subcutaneous injection once a week. Can be injected in the abdomen, thigh, or upper arm.

Mounjaro (Tirzepatide)

RxEli Lilly

Mounjaro (tirzepatide) is a once-weekly injectable prescription medicine that activates both GIP and GLP-1 receptors — the first of its kind. It is used for improving blood sugar (glucose) control in adults with type 2 diabetes mellitus, and for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Tirzepatide works by mimicking the effects of two gut hormones (GIP and GLP-1) that are naturally released after eating. These hormones reduce appetite, slow stomach emptying, and signal the pancreas to release insulin only when blood sugar is high. Key Benefits: • Significant weight reduction (up to 20–22% in clinical trials) • Improved glycaemic control in type 2 diabetes • Once-weekly convenient self-injection • Reduces cardiovascular risk factors Administration: Subcutaneous injection, once a week — same day each week. Rotate injection sites (abdomen, thigh, or upper arm).